糖尿病视网膜病变预防与治疗的当前及未来方法
Current and future approaches in the prevention and treatment of diabetic retinopathy.
作者信息
Chang Louis K, Sarraf David
机构信息
Jules Stein Eye Institute, Department of Ophthalmology, University of California, Los Angeles, Los Angeles, CA, USA.
出版信息
Clin Ophthalmol. 2008 Jun;2(2):425-33. doi: 10.2147/opth.s736.
Abstract
Diabetic retinopathy (DR) is a major cause of blindness worldwide and is the number one cause of blindness in working-age individuals in developed countries. We review the current literature and discuss the pathogenesis, modifying risk factors, genetics, and treatment of DR. Special focus is placed on the rationale and effectiveness of therapeutic modalities, both current and future.
摘要
糖尿病视网膜病变（DR）是全球失明的主要原因，也是发达国家劳动年龄人群失明的首要原因。我们回顾了当前的文献，并讨论了DR的发病机制、风险因素、遗传学和治疗方法。特别关注当前和未来治疗方式的原理和有效性。
相似文献
1
Current and future approaches in the prevention and treatment of diabetic retinopathy.糖尿病视网膜病变预防与治疗的当前及未来方法
Clin Ophthalmol. 2008 Jun;2(2):425-33. doi: 10.2147/opth.s736.
2
Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy.糖尿病视网膜病变流行病学的十大新趋势
Ophthalmic Epidemiol. 2016 Aug;23(4):209-22. doi: 10.1080/09286586.2016.1193618. Epub 2016 Jun 29.
3
Strategies to Tackle the Global Burden of Diabetic Retinopathy: From Epidemiology to Artificial Intelligence.应对糖尿病视网膜病变全球负担的策略：从流行病学到人工智能。
Ophthalmologica. 2020;243(1):9-20. doi: 10.1159/000502387. Epub 2019 Aug 13.
4
Spermine oxidase: A promising therapeutic target for neurodegeneration in diabetic retinopathy.精脒氧化酶：糖尿病性视网膜病变神经退行性变的有前途的治疗靶点。
Pharmacol Res. 2019 Sep;147:104299. doi: 10.1016/j.phrs.2019.104299. Epub 2019 Jun 15.
5
Addressing risk factors, screening, and preventative treatment for diabetic retinopathy in developing countries: a review.发展中国家糖尿病视网膜病变的危险因素、筛查及预防性治疗：综述
Clin Exp Ophthalmol. 2016 May;44(4):300-20. doi: 10.1111/ceo.12745. Epub 2016 May 1.
6
Doctor's role in early detection of diabetic retinopathy and prevention of blindness from its complications.医生在糖尿病视网膜病变早期检测及预防其并发症导致失明方面的作用。
JNMA J Nepal Med Assoc. 2005 Jan-Mar;44(157):26-30.
7
Traditional and novel risk factors of diabetic retinopathy and research challenges.糖尿病视网膜病变的传统和新型危险因素及研究挑战。
Curr Med Chem. 2013;20(26):3189-99. doi: 10.2174/09298673113209990023.
8
Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence.基于最新发病机制证据的糖尿病视网膜病变治疗新方法。
Prog Retin Eye Res. 2015 Sep;48:160-80. doi: 10.1016/j.preteyeres.2015.04.003. Epub 2015 Apr 30.
9
Therapeutic potential of curcumin in diabetic retinopathy (Review).姜黄素在糖尿病视网膜病变中的治疗潜力（综述）。
Int J Mol Med. 2021 May;47(5). doi: 10.3892/ijmm.2021.4908. Epub 2021 Mar 11.
10
MicroRNA and diabetic retinopathy-biomarkers and novel therapeutics.微小RNA与糖尿病视网膜病变——生物标志物与新型疗法
Ann Transl Med. 2021 Aug;9(15):1280. doi: 10.21037/atm-20-5189.
引用本文的文献
1
Management of Type 1 Diabetes in Pregnancy.妊娠期1型糖尿病的管理
Curr Diab Rep. 2016 Aug;16(8):76. doi: 10.1007/s11892-016-0765-z.
2
Editorial foreword.编辑前言。
Clin Ophthalmol. 2008 Jun;2(2):i-ii.
本文引用的文献
1
Laser photocoagulation combined with intravitreal triamcinolone acetonide injection in proliferative diabetic retinopathy with macular edema.激光光凝联合玻璃体内注射曲安奈德治疗增殖性糖尿病视网膜病变合并黄斑水肿
Korean J Ophthalmol. 2007 Mar;21(1):11-7. doi: 10.3341/kjo.2007.21.1.11.
2
Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes.玻璃体内注射曲安奈德联合序贯格栅样光凝与单纯曲安奈德或单纯光凝治疗糖尿病性黄斑水肿的六个月疗效
Ophthalmology. 2007 Dec;114(12):2162-7. doi: 10.1016/j.ophtha.2007.02.006. Epub 2007 Apr 25.
3
Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.玻璃体内注射贝伐单抗（阿瓦斯汀）治疗糖尿病性黄斑水肿：泛美视网膜协作研究组6个月随访结果
Ophthalmology. 2007 Apr;114(4):743-50. doi: 10.1016/j.ophtha.2006.12.028.
4
Combined triamcinolone acetonide injection and grid laser photocoagulation: a promising treatment for diffuse diabetic macular oedema?曲安奈德注射液联合格栅样激光光凝术：治疗弥漫性糖尿病性黄斑水肿的一种有前景的疗法？
Br J Ophthalmol. 2007 Apr;91(4):407-8. doi: 10.1136/bjo.2006.108753.
5
Erythropoietin levels in aqueous humour in eyes with exudative age-related macular degeneration and diabetic retinopathy.渗出性年龄相关性黄斑变性和糖尿病视网膜病变患者眼中房水中的促红细胞生成素水平。
Clin Exp Ophthalmol. 2007 Mar;35(2):186-7. doi: 10.1111/j.1442-9071.2006.01437.x.
6
Intravitreal triamcinolone as an adjunct in the treatment of concomitant proliferative diabetic retinopathy and diffuse diabetic macular oedema. Combined IVTA and laser treatment for PDR with CSMO.玻璃体内注射曲安奈德作为辅助治疗伴增殖性糖尿病视网膜病变和弥漫性糖尿病黄斑水肿。联合玻璃体内注射曲安奈德和激光治疗增殖性糖尿病视网膜病变合并糖尿病性黄斑中心凹水肿。
Int Ophthalmol. 2005 Dec;26(6):207-14. doi: 10.1007/s10792-007-9042-0. Epub 2007 Feb 14.
7
Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.鲁比前列酮对糖尿病性黄斑水肿患者的影响：PKC-DMES随机临床试验的30个月结果
Arch Ophthalmol. 2007 Mar;125(3):318-24. doi: 10.1001/archopht.125.3.318.
8
Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.玻璃体内地塞米松药物递送系统治疗持续性黄斑水肿患者的随机对照研究
Arch Ophthalmol. 2007 Mar;125(3):309-17. doi: 10.1001/archopht.125.3.309.
9
Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.细胞外碳酸酐酶通过激肽释放酶原激活介导视网膜出血和脑血管通透性。
Nat Med. 2007 Feb;13(2):181-8. doi: 10.1038/nm1534. Epub 2007 Jan 28.
10
The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy.生长激素、胰岛素样生长因子和生长抑素在糖尿病性视网膜病变中的作用。
Curr Med Chem. 2006;13(27):3307-17. doi: 10.2174/092986706778773086.
Zotero 插件